Skip to content
Screener

Praxis Precision Medicines, Inc. PRAX Q4 2025 Annual earnings

Reported February 19, 2026 · Before market open

Revenue-
EPS-$3.50Miss by $0.37
EPS estimate-$3.13

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$130.8K
EPS estimate-$3.65

Financials

Q4 2025

Income statement

See full
Revenue--100%
Operating income-$97.0M-51.7%
Net income-$88.9M-51.5%
EPS (diluted)-$3.51-17.0%

Balance sheet

See full
Cash & equivalents$357.7M+65.8%
Total debt$110.0K-92.0%
Total equity$878.1M+97.1%
Total assets$937.9M+94.1%

Cash flow

See full
Operating cash flow-$76.3M-36.0%
Free cash flow-$76.3M-36.0%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$7.37B+414%
Enterprise value$7.01B+475%

Returns & leverage

See full
Return on equity-45.8%-12.0pp
Debt / equity0×0.0×
Current ratio10.2×-0.5×

FAQ

When did Praxis Precision Medicines, Inc. report Q4 2025 earnings?
Praxis Precision Medicines, Inc. (PRAX) reported Q4 2025 earnings on February 19, 2026 before market open.
What were Praxis Precision Medicines, Inc.'s Q4 2025 revenue and EPS?
Praxis Precision Medicines, Inc. reported revenue of - and eps of $-3.50 for Q4 2025.
Did Praxis Precision Medicines, Inc. beat estimates in Q4 2025?
EPS missed the consensus estimate of $-3.13 by $0.37.
How did Praxis Precision Medicines, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $7.5M a year earlier and eps declined 19.0% from $-2.94.
Where can I find Praxis Precision Medicines, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001689548-26-000028) and the 10-K periodic report (0001689548-26-000029) directly on SEC EDGAR. The filing index links above go to sec.gov.